For human research, 500 mg per day is the clearest single resveratrol dose anchor. For a supplement label, the more important question comes first: what form does that milligram number describe?
A 2024 systematic review found that 500 mg/day was the most common defined standalone resveratrol dose, used in 32 trials. The median trial dose was 490 mg/day, and 88% of treatment groups used 1,000 mg/day or less.[1]
Trans-resveratrol is the form used in much of the human clinical literature. A bottle that lists 600 mg of botanical extract or resveratrol complex is not automatically equivalent to 600 mg of trans-resveratrol. The standardized trans-resveratrol amount is the more useful number for comparing a supplement with clinical research.
That distinction matters for CELLSHE Resveratrol 600. Each capsule contains a 600 mg resveratrol complex standardized to 50% trans-resveratrol, providing about 300 mg trans-resveratrol. The labeled two-capsule daily use therefore provides about 600 mg trans-resveratrol per day, a daily amount in the same hundreds-of-milligrams territory that dominates human research.
Resveratrol is one of the most extensively studied plant polyphenols in humans. A 2024 systematic review identified almost 200 clinical studies across at least 24 indications.[1] That depth of research is why the dosage question deserves more than a generic “take 250 to 500 mg” answer.
The useful way to read the evidence is to separate four things: the compound named in the study, the trans-resveratrol content, the total label weight, and the daily dose. Once those are separated, the research becomes far easier to compare with a real supplement label.
Evidence reviewed through September 3, 2026.
How much resveratrol should you take?
If you want one number that represents the center of human resveratrol research, 500 mg/day is the best-supported answer. The 2024 systematic review found a median daily dose of 490 mg and counted more trials at 500 mg/day than at any other single amount.[1]
But the review used “purified resveratrol” as a study-selection term. The authors defined it as a known dose of resveratrol given on its own rather than inside a mixture.[1] It is not a claim that every trial used 100% pure trans-resveratrol.
That is why “pure resveratrol,” “resveratrol,” “trans-resveratrol,” and “600 mg extract” should never be treated as automatic synonyms. The dose only becomes meaningful once the form and standardized content are clear.
Human trials also exist at 150, 200, 250 and 300 mg/day, while 1,000 mg/day is another common research dose.[1][10][11][12][15][19] The research landscape is broad, but it is concentrated in the hundreds of milligrams rather than at trace dietary amounts.
CELLSHE LABEL + RESEARCH DECODER
What a resveratrol milligram actually means
| Term | What it means | How to use the number |
|---|---|---|
| Resveratrol | The compound name. Resveratrol exists mainly as trans and cis geometric isomers. | Useful only when the study or label also makes the form and amount clear. |
| Trans-resveratrol | The trans isomer. It is the form used in much of the human clinical literature. | This is the most useful active-form number for comparing standardized supplements with trans-resveratrol studies. |
| Cis-resveratrol | The cis isomer, which has a much smaller human clinical evidence base. | Do not assume a total “resveratrol” number tells you how much is trans versus cis. |
| “Purified resveratrol” in Brown et al. | A defined dose of resveratrol administered on its own rather than as part of a mixture.[1] | It is a study-inclusion category, not a 100% purity guarantee and not a synonym for trans-resveratrol. |
| Botanical extract or resveratrol complex | The total weight of source material or complex shown on a supplement label. | Look for a standardized percentage or stated trans-resveratrol amount before comparing it with a study dose. |
| 600 mg complex standardized to 50% trans | About 300 mg trans-resveratrol from a 600 mg complex. | The 300 mg trans number, not the 600 mg headline alone, is the closest ingredient-level comparison point. |
Source: Brown et al. for the systematic-review definition, plus direct human trans-resveratrol pharmacokinetic studies in References 5 to 7.[1][5][6][7]
Why resveratrol remains scientifically interesting: the 2024 review found an expanding human evidence base across metabolic, inflammatory and other clinical endpoints. Across the literature it reviewed, resveratrol consistently reduced inflammatory markers and improved aspects of dysregulated metabolism.[1]
At the 500 mg/day research anchor, a randomized crossover trial studied 50 healthy adult smokers. Resveratrol raised total antioxidant status while lowering CRP and triglycerides versus placebo.[20] Different populations produce different outcomes, but this is direct human evidence that the hundreds-of-milligrams range is biologically active, not an arbitrary supplement convention.
150 to 300 mg/day: an established lower research range.
Human studies at 150, 200, 250 and 300 mg/day span healthy older adults, postmenopausal women and metabolic populations.[10][11][12][15][19] A 250 mg/day randomized study in adults with type 2 diabetes reported improvements in several glycemic and cardiovascular measures.[19]
500 mg/day: the strongest single research anchor.
It is the most common defined standalone dose in the 2024 clinical-trial review.[1] In a randomized crossover trial in healthy smokers, 500 mg/day also increased total antioxidant status and reduced CRP and triglycerides versus placebo.[20]
1,000 mg/day: another well-represented clinical dose.
One gram per day appears in 26 trials in the 2024 review, including pharmacology, safety and disease-specific research.[1][9][12]
2,500 to 5,000 mg/day: multi-gram research territory.
These amounts are concentrated in pharmacokinetic, safety and disease-specific protocols. A 29-day healthy-volunteer study found more gastrointestinal symptoms in the 2.5 and 5 g groups.[8]
What do 150 to 300 mg resveratrol studies show?
Doses from 150 to 300 mg/day form a meaningful lower part of the human research landscape. Direct human studies exist at 150, 200, 250 and 300 mg/day. These doses have been tested for periods ranging from 30 days to 12 months in several adult populations.[10][11][12][15][19]
At 250 mg/day, a three-month open-label randomized trial in 62 adults with type 2 diabetes reported improvements in several glycemic and cardiovascular measures.[19] At 150 mg/day, other trials have produced both positive and null findings depending on the population and endpoint.[10][16] The useful conclusion is that 250 mg is a studied dose, while the outcome evidence remains study-specific.
What doses have human resveratrol studies actually used?
Representative trials show why the form belongs beside the dose. Some papers explicitly use trans-resveratrol. Others report “resveratrol” without enough formulation detail to make a precise purity comparison. A rigorous dose map should preserve that difference rather than silently treating every milligram as identical.
CELLSHE EVIDENCE MAP
Resveratrol doses in human trials, with the study context attached
| Study | Population | Daily dose | Duration | Main endpoint or question | What the study adds to the dose picture |
|---|---|---|---|---|---|
| Timmers et al., 2011[10] | 11 men with obesity, otherwise healthy | 150 mg/day trans-resveratrol | 30 days | Energy metabolism, mitochondrial and metabolic measures | A relatively low dose produced several metabolic and mitochondrial changes in this small crossover trial. |
| Witte et al., 2014[11] | 46 healthy overweight adults, ages 50 to 75 | 200 mg/day | 26 weeks | Memory, hippocampal connectivity and metabolic measures | Shows that a 200 mg dose has been studied for six months in older adults, with memory and metabolic signals reported. |
| Anton et al., 2014[12] | 32 overweight older adults, mean age 73 | 300 or 1,000 mg/day | 90 days | Safety and metabolic outcomes | A direct two-dose safety comparison found no significant difference in participants reporting adverse events across groups during 90 days. |
| Turner et al., 2015[13] | 119 people with mild to moderate Alzheimer disease | Started at 500 mg/day; escalated to 2,000 mg/day | 52 weeks | Safety, pharmacokinetics, brain and fluid biomarkers | A long high-dose disease trial. The population and biomarker endpoints make it a poor basis for general wellness dosing. |
| Bo et al., 2016[14] | 192 adults with type 2 diabetes | 40 or 500 mg/day | 6 months | CRP and metabolic outcomes | A direct dose comparison found no significant improvement in the primary inflammatory or metabolic pattern at either dose. |
| Zaw et al., 2021[15] | 125 postmenopausal women, ages 45 to 85 | 150 mg/day, given as 75 mg twice daily | 12 months per crossover period | Cognition, cerebrovascular and cardiometabolic measures | Provides long-duration evidence at a lower daily dose in a defined female population. |
| de Ligt et al., 2020[16] | 41 overweight men and postmenopausal women, ages 40 to 70 | 150 mg/day | 6 months | Insulin sensitivity and metabolic outcomes | The primary insulin-sensitivity endpoint did not improve, showing that a dose cannot be judged apart from the endpoint tested. |
| Nguyen et al., 2024[17] | 142 adults with painful knee osteoarthritis | 80 mg/day for 1 week, then 40 mg/day | 6 months | Knee pain | A patented formulation was tested at low doses. The trial did not improve the primary pain endpoint versus placebo. |
| Wightman et al., 2026[18] | 99 adults with overweight or obesity, ages 35 to 60 | 500 mg/day | 12 weeks | Cognition, microbiome, inflammation and adiposity markers | The newest trial in this map found no significant changes in microbiome, inflammation or adiposity markers, despite using the most common research dose. |
Source: Peer-reviewed human studies in References 10 to 18. CELLSHE interpretation: the useful unit is form + actual active amount + population + duration + endpoint.
Is 500 mg of resveratrol a meaningful dose?
Yes. Five hundred milligrams per day is the most common single defined resveratrol dose in the 2024 human trial review. The review counted 32 trials at this amount.[1]
It is also a biologically meaningful human dose. In 50 healthy adult smokers, 500 mg/day for 30 days increased total antioxidant status by 74.2 µmol/L versus placebo and reduced CRP and triglyceride concentrations.[20]
Other 500 mg studies have produced different results because the populations and endpoints were different. A 2026 trial in adults with overweight or obesity found no significant change in its microbiome, inflammatory or adiposity outcomes.[18] A six-month type 2 diabetes trial also found no significant improvement in its primary CRP pattern.[14]
The practical reading is strong and simple: 500 mg is a central human research dose, but it is not one universal outcome guarantee. When a supplement is standardized to trans-resveratrol, compare the stated trans amount with the study compound before comparing the headline milligrams.
What does 1,000 mg of resveratrol mean in the research?
One gram per day is another common human research dose. At this level, tolerability and medication interactions deserve more attention.
The 2024 trial review found 26 trials using 1,000 mg/day.[1] A 90-day placebo-controlled pilot studied 300 and 1,000 mg/day in overweight older adults. Both doses were well tolerated during the study, with no significant difference in participants reporting adverse events across groups.[12]
A separate healthy-volunteer study used 1,000 mg/day for four weeks and measured drug-metabolizing enzymes. Resveratrol altered phenotypic indices for CYP3A4, CYP2D6, CYP2C9 and CYP1A2.[9] That finding is one reason the safety question cannot be reduced to a single milligram ceiling.
For a fuller review of adverse effects, higher-dose gastrointestinal findings and medication considerations, see our dedicated guide to resveratrol side effects.
Does a higher resveratrol dose work better?
A higher resveratrol dose can increase exposure, but the best research dose depends on the endpoint being studied. Human trials have not produced a universal higher-is-better pattern, and direct dose-response comparisons remain relatively uncommon.[1]
The clearest demonstration comes from trials that directly compare doses. In 192 adults with type 2 diabetes, 40 and 500 mg/day were tested for six months. Neither dose significantly improved the primary CRP or metabolic pattern versus placebo.[14] In the older-adult safety pilot, both 300 and 1,000 mg/day were tolerated during 90 days.[12] The trial was not designed to prove that the higher dose produced a superior health outcome.
At the far upper end, 0.5, 1, 2.5 and 5 g/day were tested for 29 days in healthy volunteers. Mild to moderate gastrointestinal symptoms were concentrated in the 2.5 and 5 g groups.[8] Higher exposure therefore can bring a higher tolerability cost without establishing a better clinical result.
The newest broad synthesis reaches the same practical conclusion from another direction. A 2026 umbrella review evaluated 45 systematic reviews across 68 outcomes and found effects varied by outcome and population.[2] Resveratrol evidence is strongly tied to the outcome and population being studied.
For the outcome-by-outcome efficacy question, see our separate review of resveratrol benefits. This page stays focused on dose, timing, exposure and tolerability.
When is the best time to take resveratrol, morning or night?
Morning has the clearest direct human pharmacokinetic signal. A morning routine is therefore a reasonable evidence-aligned choice when consistency is the goal, although health outcomes have not been directly compared morning versus night.
In a 2009 randomized pharmacokinetic study, healthy adults received 25, 50, 100 or 150 mg of trans-resveratrol six times per day for 13 doses. Resveratrol exposure varied by time of day, and bioavailability was higher after morning administration.[6]
That study measured pharmacokinetics, not sleep, energy, cognition, blood pressure or longevity. It therefore supports a narrow conclusion: time of day can change measured resveratrol exposure. Clinical superiority for a morning routine remains untested.
Many resveratrol trials happen to use morning, evening or split dosing schedules. A protocol schedule is not evidence that the schedule itself improved the outcome.
Should you take resveratrol with food or on an empty stomach?
The strongest direct human pharmacokinetic evidence shows that a high-fat meal can delay resveratrol absorption without meaningfully increasing total exposure. A second very-high-dose study found lower exposure after a high-fat breakfast.
CELLSHE ANALYSIS
What direct human studies actually show about food and timing
| Question | Human study | Protocol | Result | Best interpretation |
|---|---|---|---|---|
| High-fat meal vs fasting | Vaz-da-Silva et al., 2008[5] | 24 healthy adults; single 400 mg trans-resveratrol dose | Median time to peak was 2.0 hours fed vs 0.5 hours fasted. Total exposure by AUC was not affected in a relevant way. | Food delayed absorption, while total exposure remained broadly similar. |
| High-fat vs standard breakfast | la Porte et al., 2010[7] | 8 healthy adults; 2,000 mg twice daily at steady state | High-fat breakfast reduced 12-hour AUC by 45% and Cmax by 46% versus a standard breakfast. | At this very high dose, more dietary fat reduced resveratrol exposure rather than increasing it. |
| Morning vs later doses | Almeida et al., 2009[6] | Healthy adults; 25 to 150 mg six times daily for 13 doses | Pharmacokinetics showed circadian variation, with higher bioavailability after morning administration. | Morning exposure was higher in this PK protocol. Clinical outcome superiority was not tested. |
CELLSHE interpretation: meal composition and clock time can alter resveratrol pharmacokinetics. The direct human data favor a study-specific reading over a universal “take it with fat” rule, and long-term outcome comparisons between schedules remain untested.
This is one of the clearest places where consumer guidance has outrun the evidence. Resveratrol produces low circulating levels of unchanged parent compound after oral dosing. A high-fat meal has not shown a consistent exposure advantage in direct human studies.[3][5]
How is resveratrol absorbed and metabolized?
Resveratrol is absorbed efficiently, then rapidly converted into metabolites. In a classic radiolabeled human study, at least 70% of a 25 mg dose was absorbed, while only trace unchanged resveratrol remained in plasma because metabolism was extensive.[3]
A later single-dose escalation study tested 0.5, 1, 2.5 and 5 g in healthy adults. Plasma exposure to several glucuronide and sulfate metabolites greatly exceeded exposure to unchanged resveratrol.[4] The 29-day repeat-dose study found the same broad pattern, with metabolite exposure far above the parent compound.[8]
This explains why the label number and the blood concentration of unchanged resveratrol are not directly interchangeable. It also explains why formulation matters. A specialized formulation needs its own evidence before its milligram dose is compared directly with standard trans-resveratrol.
How do you compare a resveratrol label with a clinical trial?
Start with the trans-resveratrol amount, not the largest number printed on the front. A botanical extract or “resveratrol complex” can weigh much more than the trans-resveratrol it actually supplies.
Then check the standardized percentage. A 600 mg complex standardized to 50% trans-resveratrol provides about 300 mg trans-resveratrol. Two such capsules provide about 600 mg trans-resveratrol across the day.
“Pure resveratrol” is also too vague unless a purity percentage and isomer are stated. In scientific writing, “purified resveratrol” can simply mean isolated resveratrol rather than a mixture. Brown et al. use the term in exactly that methodological sense.[1]
The trans isomer has the clearest clinical relevance. Direct human pharmacokinetic studies explicitly administered trans-resveratrol, and much of the broader clinical literature centers on this form.[5][6][7] Our dedicated guide to trans-resveratrol explains the isomer distinction in more detail.
How CELLSHE Resveratrol 600 maps to this framework
- Per capsule: 600 mg resveratrol complex.
- Standardization: 50% trans-resveratrol.
- Actual trans-resveratrol: about 300 mg per capsule.
- Labeled daily use: one capsule twice daily, about 600 mg trans-resveratrol per day.
- Research context: that daily trans amount sits close to the 500 mg/day center of the human resveratrol dose landscape and well below multi-gram research protocols.
For product-quality questions such as standardization, testing and label transparency, see our guide to choosing the best resveratrol supplement.
CELLSHE TOOL
The Resveratrol Study-Dose Decoder
| Check | What to record | Why it changes the meaning of the dose |
|---|---|---|
| □ 1. Exact compound | Trans-resveratrol, resveratrol with unspecified isomer, botanical extract, or named formulation | The same headline milligrams can describe different material. Record the exact form before comparing doses. |
| □ 2. Actual daily dose | _____ mg/day | Separate active resveratrol from total extract weight and capsule count. |
| □ 3. Dose schedule | Single dose, once daily, twice daily, or another split: __________ | A 1,000 mg daily total can represent very different exposure patterns. |
| □ 4. Population | Healthy adults, older adults, postmenopausal women, diabetes, another condition: __________ | Results belong to the people actually studied. |
| □ 5. Duration | Single dose / _____ days / _____ weeks / _____ months | Short pharmacology and long intervention trials answer different questions. |
| □ 6. Primary endpoint | Blood exposure, biomarker, symptoms, function, clinical outcome: __________ | A dose that changes a biomarker has not automatically improved health or function. |
| □ 7. Comparator | Placebo, lower dose, higher dose, baseline only, or active treatment: __________ | A dose cannot establish superiority without the right comparison. |
| □ 8. Dose-response tested? | Yes / No | Most resveratrol RCTs did not directly compare several doses. |
| □ 9. Adverse events and withdrawals | ________________________________________ | Tolerability belongs beside dose and duration, especially at higher amounts. |
| □ 10. Result in one sentence | ________________________________________ | Write what changed, in whom, at what dose, without upgrading the endpoint. |
Source: CELLSHE synthesis based on the trial-design problems identified in the 2024 systematic review of purified-resveratrol clinical trials.[1]
How does dose change the resveratrol safety picture?
The hundreds-of-milligrams range is well represented in human trials and generally well tolerated over the studied periods. Gastrointestinal problems become more prominent in multi-gram protocols, which is a different dose territory from standard hundreds-of-milligrams supplementation.
The 2024 systematic review concluded that resveratrol was generally well tolerated at up to 1 g/day across the clinical literature it reviewed.[1] The 90-day older-adult study found favorable tolerability at 300 and 1,000 mg/day.[12]
At 2.5 and 5 g/day for 29 days, gastrointestinal symptoms such as nausea, abdominal discomfort, flatulence and diarrhea were more common.[8] A separate very-high-dose study using 2 g twice daily reported diarrhea in six of eight healthy participants.[7]
Medication context matters too. The four-week 1 g/day study changed several drug-metabolizing enzyme indices.[9] People taking prescription medicines should therefore treat medication compatibility as a separate question from whether a dose was tolerated in a research trial.
Longer exposure has also been studied in selected populations. Examples include 12 months at 150 mg/day in postmenopausal women and a 52-week escalating high-dose Alzheimer disease protocol.[15][13] Those studies expand the duration map, while a single long-term safety limit across all adults remains undefined.
What is the most useful resveratrol dosage takeaway?
For the research literature, 500 mg/day is the clearest single dose anchor. For a supplement label, the trans-resveratrol amount is the number that deserves your attention first. The 2024 systematic review places the median trial dose at 490 mg/day, with 500 mg/day the most common single amount.[1]
That makes a standardized trans-resveratrol product in the hundreds-of-milligrams range scientifically coherent. CELLSHE Resveratrol 600 provides about 300 mg trans-resveratrol per capsule and about 600 mg/day when used as labeled. Its active-form amount therefore sits close to the center of the human dose landscape, far below multi-gram research territory.
The final comparison should still keep form, population, duration and endpoint attached to the milligram number. That is the difference between reading a supplement label intelligently and simply choosing the biggest number on the bottle.
References
- Brown K, et al. (2024). Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities. International Journal of Molecular Sciences. PMID: 38255828. PubMed.
- Sun JN, et al. (2026). Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Nutrition Journal. PMID: 41987155. PubMed.
- Walle T, et al. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition. PMID: 15333514. PubMed.
- Boocock DJ, et al. (2007). Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology, Biomarkers & Prevention. PMID: 17548692. PubMed.
- Vaz-da-Silva M, et al. (2008). Effect of food on the pharmacokinetic profile of trans-resveratrol. International Journal of Clinical Pharmacology and Therapeutics. PMID: 19000554. PubMed.
- Almeida L, et al. (2009). Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Molecular Nutrition & Food Research. PMID: 19194969. PubMed.
- la Porte C, et al. (2010). Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clinical Pharmacokinetics. PMID: 20528005. PubMed.
- Brown VA, et al. (2010). Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Research. PMID: 20935227. PubMed.
- Chow HHS, et al. (2010). Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prevention Research. PMID: 20716633. PubMed.
- Timmers S, et al. (2011). Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metabolism. PMID: 22055504. PubMed.
- Witte AV, et al. (2014). Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. Journal of Neuroscience. PMID: 24899709. PubMed.
- Anton SD, et al. (2014). Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Experimental Gerontology. PMID: 24866496. PubMed.
- Turner RS, et al. (2015). A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. PMID: 26362286. PubMed.
- Bo S, et al. (2016). Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacological Research. PMID: 27520400. PubMed.
- Zaw JJT, et al. (2021). Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study. Clinical Nutrition. PMID: 32900519. PubMed.
- de Ligt M, et al. (2020). No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial. American Journal of Clinical Nutrition. PMID: 32492138. PubMed.
- Nguyen C, et al. (2024). Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL). PLOS Medicine. PMID: 39137167. PubMed.
- Wightman E, et al. (2026). The effects of 12-weeks resveratrol supplementation on cognition, gastrointestinal microbiota, and systemic inflammation, in an overweight and obese human population: a randomized, double-blind, placebo controlled, parallel groups trial. Frontiers in Nutrition. PMID: 42459802. PubMed.
- Bhatt JK, Thomas S, Nanjan MJ. (2012). Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition Research. PMID: 22901562. PubMed.
- Bo S, et al. (2013). Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers: a randomized, double-blind, placebo-controlled, cross-over trial. Current Medicinal Chemistry. PMID: 23298135. PubMed.
